Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates
- PMID: 34524678
- DOI: 10.1007/s40618-021-01676-4
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates
Abstract
Purpose: An increased fracture risk is commonly reported in Duchenne muscular dystrophy (DMD). Our aim was to investigate bone mineral density (BMD) and bone turnover, including sclerostin, and their association with markers of cardiac and respiratory performance in a cohort of DMD subjects.
Methods: In this single center, cross sectional observational study, lumbar spine (LS) BMD Z-scores, C-terminal telopeptide of procollagen type I (CTX) and osteocalcin (BGP), as bone resorption and formation markers, respectively, and sclerostin were assessed. Left ventricular ejection fraction (LVEF) and forced vital capacity (FVC) were evaluated. Clinical prevalent fractures were also recorded.
Results: Thirty-one patients [median age = 14 (12-21.5) years] were studied. Ambulant subjects had higher LS BMD Z-scores compared with non-ambulant ones and subjects with prevalent clinical fractures [n = 9 (29%)] showed lower LS BMD Z-scores compared with subjects without fractures. LS BMD Z-scores were positively correlated with FVC (r = 0.50; p = 0.01), but not with glucocorticoid use, and FVC was positively associated with BGP (r = 0.55; p = 0.02). In non-ambulant subjects, LS BMD Z-scores were associated with BMI (r = 0.54; p = 0.02) and sclerostin was associated with age (r = 0.44; p = 0.05). Age, BMI, FVC and sclerostin were independently associated with LS BMD Z-score in a stepwise multiple regression analysis. Older age, lower BMI, FVC and sclerostin were associated with lower LS BMD Z-scores.
Conclusion: In a cohort of DMD patients, our data confirm low LS BMD Z-scores, mainly in non-ambulant subjects and irrespective of the glucocorticoid use, and suggest that FVC and sclerostin are independently associated with LS BMD Z-scores.
Keywords: Bone mineral density; Bone turnover; Duchenne muscular dystrophy; Forced vital capacity; Fractures; Glucocorticoid; Left ventricular ejection fraction; Sclerostin.
© 2021. Italian Society of Endocrinology (SIE).
Comment in
-
Bone quality in Duchenne muscular dystrophy.J Endocrinol Invest. 2022 Jun;45(6):1265-1266. doi: 10.1007/s40618-022-01783-w. Epub 2022 Mar 10. J Endocrinol Invest. 2022. PMID: 35267176 No abstract available.
References
-
- Dalkilic I, Kunkel LM (2003) Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev 13(3):231–238. https://doi.org/10.1016/s0959-437x(03)00048-0 - DOI - PubMed
-
- Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY (2016) Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003725.pub4 - DOI - PubMed - PMC
-
- Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17(4):347–361. https://doi.org/10.1016/S1474-4422(18)30025-5 - DOI - PubMed - PMC
-
- Mayo AL, Craven BC, McAdam LC, Biggar WD (2012) Bone health in boys with Duchenne muscular dystrophy on long-term daily deflazacort therapy. Neuromuscul Disord 22(12):1040–1045. https://doi.org/10.1016/j.nmd.2012.06.354 - DOI - PubMed
-
- Buckner JL, Bowden SA, Mahan JD (2015) Optimizing bone health in duchenne muscular dystrophy. Int J Endocrinol 2015:928385. https://doi.org/10.1155/2015/928385 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
